TY - JOUR
T1 - Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer
AU - Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium
AU - Ganguli, Piyali
AU - Basanta, Celia C.
AU - Acha-Sagredo, Amelia
AU - Misetic, Hrvoje
AU - Armero, Maria
AU - Mendez, Akram
AU - Zahra, Aeman
AU - Devonshire, Ginny
AU - Kelly, Gavin
AU - Freeman, Adam
AU - Green, Mary
AU - Nye, Emma
AU - Bichisecchi, Anita
AU - Bonfanti, Paola
AU - Bartlett, Freddie
AU - Petty, Russell D.
AU - Coleman, Helen
AU - McManus, Damian
AU - Turkington, Richard
AU - Grabowska, Anna
AU - Moorthy, Krishna
AU - Peters, Christopher J.
AU - Hanna, George B.
AU - Lishman, Suzy
AU - Sothi, Sharmila
AU - Scott, Michael
AU - Haidry, Rehan
AU - Lovat, Laurence
AU - Saunders, John
AU - Kaye, Philip
AU - Soomro, Irshad
AU - Parsons, Simon L.
AU - Sreedharan, L.
AU - Kumar, Bhaskar
AU - Cheong, Ed
AU - Chan, David
AU - Berrisford, Richard
AU - Sanders, Grant
AU - Ciccarelli, Francesca D.
AU - Goh, Vicky
AU - Mahadeva, Ula
AU - Chang, Fuju
AU - Davies, Andrew
AU - Gossage, James
AU - Lagergren, Jesper
AU - Grace, Ben L.
AU - Walker, Robert C.
AU - Underwood, Timothy J.
AU - Contino, Gianmarco
AU - Ciccarelli, Francesca D.
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/1/1
Y1 - 2025/1/1
N2 - CDKN2A is a tumor suppressor located in chromosome 9p21 and frequently lost in Barrett’s esophagus (BE) and esophageal adenocarcinoma (EAC). How CDKN2A and other 9p21 gene co-deletions affect EAC evolution remains understudied. We explored the effects of 9p21 loss in EACs and cancer progressor and non-progressor BEs with matched genomic, transcriptomic and clinical data. Despite its cancer driver role, CDKN2A loss in BE prevents EAC initiation by counterselecting subsequent TP53 alterations. 9p21 gene co-deletions predict poor patient survival in EAC but not BE through context-dependent effects on cell cycle, oxidative phosphorylation and interferon response. Immune quantifications using bulk transcriptome, RNAscope and high-dimensional tissue imaging showed that IFNE loss reduces immune infiltration in BE, but not EAC. Mechanistically, CDKN2A loss suppresses the maintenance of squamous epithelium, contributing to a more aggressive phenotype. Our study demonstrates context-dependent roles of cancer genes during disease evolution, with consequences for cancer detection and patient management.
AB - CDKN2A is a tumor suppressor located in chromosome 9p21 and frequently lost in Barrett’s esophagus (BE) and esophageal adenocarcinoma (EAC). How CDKN2A and other 9p21 gene co-deletions affect EAC evolution remains understudied. We explored the effects of 9p21 loss in EACs and cancer progressor and non-progressor BEs with matched genomic, transcriptomic and clinical data. Despite its cancer driver role, CDKN2A loss in BE prevents EAC initiation by counterselecting subsequent TP53 alterations. 9p21 gene co-deletions predict poor patient survival in EAC but not BE through context-dependent effects on cell cycle, oxidative phosphorylation and interferon response. Immune quantifications using bulk transcriptome, RNAscope and high-dimensional tissue imaging showed that IFNE loss reduces immune infiltration in BE, but not EAC. Mechanistically, CDKN2A loss suppresses the maintenance of squamous epithelium, contributing to a more aggressive phenotype. Our study demonstrates context-dependent roles of cancer genes during disease evolution, with consequences for cancer detection and patient management.
UR - http://www.scopus.com/inward/record.url?scp=85213940578&partnerID=8YFLogxK
U2 - 10.1038/s43018-024-00876-0
DO - 10.1038/s43018-024-00876-0
M3 - Article
C2 - 39753721
AN - SCOPUS:85213940578
SN - 2662-1347
VL - 6
SP - 158
EP - 174
JO - Nature Cancer
JF - Nature Cancer
IS - 1
M1 - 35
ER -